VANCOUVER, BC — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the… Read More
DJSI World Highlights the Most Sustainable Companies Around the WorldBased on Corporate Sustainability Assessment Ranking Reflects Gilead’s Ongoing Commitment to Corporate Responsibility FOSTER CITY, CA — (BUSINESS WIRE) — Gilead… Read More
Results show overall confirmed objective response rate (cORR) of 33%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 9.6 months Data support further investigation of zanidatamab… Read More
New clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy. Clinical trial dosing will use Numinus Bioscience’s Psilocybin Tea, EnfiniTea – one of the first Phase 1 clinical… Read More
Canary Quantiles™ Recovery Curves Compare Observed Gait Performance versus Population Gait Performance During a Patient’s Recovery from Total Knee Replacement Surgery Quantiles™ Recovery Curves Utilize Data Derived from Persona IQ® to Help Healthcare Professionals… Read More
